← Patent-cliff monitor small molecule INQOVI CEDAZURIDINE; DECITABINE
Loss of exclusivity December 2042 latest FDA-listed patent expiry
Drug detail Brand name INQOVI Active ingredient CEDAZURIDINE; DECITABINE Strength 100MG;35MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval July 2020 Marketing status RX
Listed patents Patent Expires Type 12697347 December 2042 use U-4587 12239653 February 2041 use U-2866 11963971 February 2041 product 12195496 October 2040 product 8268800 February 2034 substance 8618075 October 2028 use U-2867 9567363 October 2028 substance
Regulatory exclusivity Code Expires I-990 May 2029 ODE-316 July 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.